Treatment with the first Russian direct-acting antiviral drug in patients with chronic hepatitis C

2019 ◽  
Vol 4_2019 ◽  
pp. 77-83
Author(s):  
Ponezheva Zh.B. Ponezheva ◽  
Makashova V.V. Makashova ◽  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Antiviral Drug ◽  
Direct Acting Antiviral ◽  
Direct Acting

Su1466 The Beneficial Effects on Liver Function After Administration of a Direct Acting Antiviral Drug Therapy in Chronic Hepatitis C

2016 ◽  
Vol 150 (4) ◽  
pp. S1107
Author(s):  
Yasuhiro Tsuda ◽  
Keisuke Yokohama ◽  
Ken Nakamura ◽  
Hideko Ohama ◽  
Tetsuya Sujishi ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Drug Therapy ◽  
Liver Function ◽  
Chronic Hepatitis C ◽  
Antiviral Drug ◽  
Direct Acting Antiviral ◽  
Beneficial Effects ◽  
Direct Acting

Asymptomatic chronic hepatitis c with F0-1 fibrosis: Wait and monitor

2018 ◽  
Vol 1 (2) ◽  
pp. 5-8
Author(s):  
Chanunta Hongthanakorn
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Antiviral Drug ◽  
Sustained Viral Response ◽  
Direct Acting Antiviral ◽  
Non Invasive ◽  
Invasive Test ◽  
New Treatment ◽  
Direct Acting

The short-term progression of asymptomatic chronic hepatitis C patients with mild fibrosis isexcellent. Non-invasive test is easy and use to monitor the progression of fibrosis. Interferon regimen isthe treatment for HCV patients, currently direct-acting antiviral drug (DDA) regimens is more effectiveand shorter duration. Many DDA regimens can have sustained viral response (SVR) rates of morethan 90% and safety outcomes. Furthermore, all-oral interferon free regimens are not cost-effectivefor patients with mild fibrosis disease. The HCV treatment should be deferred for a few years and theprogression of fibrosis is regularly monitored. This option is safe until new treatment, which ischeaper, shorter, more effective and more convenient, become available.   Keywords: symptomatic, direct-acting antiviral drug, fibrosis progression, cost

scholarly journals Assessment of Liver Stiffness Regression and Hepatocellular Carcinoma Risk in Chronic Hepatitis C Patients after Treatment with Direct-Acting Antiviral Drugs

Medicina ◽  
2021 ◽  
Vol 57 (3) ◽  
pp. 210
Author(s):  
Martynas Ridziauskas ◽  
Birutė Zablockienė ◽  
Ligita Jančorienė ◽  
Artūras Samuilis ◽  
Rolandas Zablockis ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Liver Stiffness ◽  
Direct Acting Antiviral ◽  
End Of Treatment ◽  
Increased Risk ◽  
Patients With Diabetes ◽  
Direct Acting

Background and Objectives: Chronic hepatitis C virus infection affects about 71 million people worldwide. It is one of the most common chronic liver conditions associated with an increased risk of developing liver cirrhosis and cancer. The aim of this study was to evaluate changes in liver fibrosis and the risk of developing hepatocellular carcinoma after direct-acting antiviral drug therapy, and to assess factors, linked with these outcomes. Materials and Methods: 70 chronic hepatitis C patients were evaluated for factors linked to increased risk of de novo liver cancer and ≥ 20% decrease of ultrasound transient elastography values 12 weeks after the end of treatment. Results: The primary outcome was an improvement of liver stiffness at the end of treatment (p = 0.004), except for patients with diabetes mellitus type 2 (p = 0.49). Logistic regression analysis revealed factors associated with ≥ 20% decrease of liver stiffness values: lower degree of steatosis in liver tissue biopsy (p = 0.053); no history of interferon-based therapy (p = 0.045); elevated liver enzymes (p = 0.023–0.036); higher baseline liver stiffness value (p = 0.045) and absence of splenomegaly (p = 0.035). Hepatocellular carcinoma developed in 4 (5.7%) patients, all with high alpha-fetoprotein values (p = 0.0043) and hypoechoic liver mass (p = 0.0001), three of these patients had diabetes mellitus type 2. Conclusions: Liver stiffness decrease was significant as early as 12 weeks after the end of treatment. Patients with diabetes and advanced liver disease are at higher risk of developing non-regressive fibrosis and hepatocellular carcinoma even after successful treatment.

scholarly journals Hepatitis C virus vaccine development: old challenges and new opportunities

2015 ◽  
Vol 2 (3) ◽  
pp. 285-295 ◽  
Author(s):  
Dapeng Li ◽  
Zhong Huang ◽  
Jin Zhong
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Vaccine Development ◽  
Rna Virus ◽  
Antiviral Agents ◽  
Resistance Mutations ◽  
Direct Acting Antiviral ◽  
Direct Acting

Abstract Hepatitis C virus (HCV), an enveloped positive-sense single-stranded RNA virus, can cause chronic and end-stage liver diseases. Approximately 185 million people worldwide are infected with HCV. Tremendous progress has been achieved in the therapeutics of chronic hepatitis C thanks to the development of direct-acting antiviral agents (DAAs), but the worldwide use of these highly effective DAAs is limited due to their high treatment cost. In addition, drug-resistance mutations remain a potential problem as DAAs are becoming a standard therapy for chronic hepatitis C. Unfortunately, no vaccine is available for preventing new HCV infection. Therefore, HCV still imposes a big threat to human public health, and the worldwide eradication of HCV is critically dependent on an effective HCV vaccine. In this review, we summarize recent progresses on HCV vaccine development and present our views on the rationale and strategy to develop an effective HCV vaccine.

Sign in / Sign up

Export Citation Format

Share Document